Under construction – not a live service
Sign in
Enrolling by invitationNo phase

Post Market Clinical Follow-Up Study for EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert

Key facts

Who runs it
MicroPort Orthopedics Inc.
Where
Fremont, United StatesSee the siteAlso in 1 other country, 1 site
Trial code
Status
Enrolling by invitation
People taking part
150 people, planned
Started
27 Jan 2022
Expected to end
Jan 2035
Type of study
Observational
Treatments tested
  • EVOLUTION® NitrX™
Record updated
20 March 2024

Who can take part

Age
21 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Has previously undergone or currently has determined to undergo a primary TKA with the specified combination of components: EVOLUTION® NitrX™ CS/CR Non-Porous Femur, EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® CS Tibial Insert
  • Has previously undergone or currently has determined to undergo a primary TKA for any of the following:; non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, or avascular necrosis; inflammatory degenerative joint disease including rheumatoid arthritis; correction of functional deformity
  • Willing to voluntarily sign the informed consent form
  • Willing and able to comply with the protocol, able to read and complete the required forms, and willing and able to adhere to the requirements of the protocol through the 10-year postoperative follow-up visit
  • Previously implanted subjects must be enrolled within 14 months of their primary TKA implantation; Prospective enrollment of a previously unimplanted contralateral knee is permitted in this study provided:
  • the specified combination of components (EVOLUTION® NitrX™ CS/CR Non-Porous Femur, EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® CS Tibial Insert) are used,
  • all other aspects of the Inclusion/Exclusion Criteria are satisfied,
  • enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and
  • the subject agrees to a second Informed Consent document and data collection specific to the second TKA; Bilateral subjects can have both TKAs enrolled in the study provided:
  • the specified combination of components (EVOLUTION® NitrX™ CS/CR Non-Porous Femur, EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® CS Tibial Insert) were implanted in both,
  • all other aspects of the Inclusion/Exclusion Criteria are satisfied,
  • enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and
  • the subject agrees to a second Informed Consent document and data collection specific to the second TKA; Bilateral implantation can occur at different time periods for the same subject

Who cannot take part

  • Has or had inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable
  • Has or had an overt infection at the time of implantation
  • Has or had a distant foci of infections (which may cause hematogenous spread to the implant site) at the time of implantation
  • Has or had a rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram at the time of implantation
  • Has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study
  • Has a medical condition, as judged by the Investigator, that would interfere with the subject's ability to comply with the requirements of the protocol
  • Skeletally immature (less than 21 years of age) at time of implantation
  • Currently enrolled in another clinical investigation which could affect the endpoints of this protocol
  • Has documented substance abuse issues
  • Currently incarcerated or has impending incarceration

Where in United States

Also in 1 other country, 1 site

  • Sah Orthopaedic AssociatesFremont, United StatesNo longer taking part

About the trial

What the trial wants to find out

MicroPort Orthopedics Inc. (MPO) plans to market the EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® NitrX™ CS/CR Non-Porous Femur with the EVOLUTION® Cruciate Sacrificing (CS) Tibial Insert globally, including in the European Union (EU). MPO is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and effectiveness of the EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® NitrX™ CS/CR Non-Porous Femur. These components are used along with the EVOLUTION® Cruciate Sacrificing (CS) Tibial Insert components that is marketed in the European Union (EU). This type of data collection is required by regulatory authorities for all TKA devices that do not have medium to long-term clinical evidence available.

The group in the trial

  • Newly or previously implanted patients

    Multicenter, non-interventional prospective follow-up of newly or previously implanted subjects. Previously implanted subjects must be enrolled within 14 months of the study index surgery. Single study group with either newly or previously implanted patients with all EVOLUTION® NitrX™ components: Non-Porous Keeled Tibia, CS/CR Non-Porous Femur component, and EVOLUTION® MP CS tibial insert

    Treatment: EVOLUTION® NitrX™

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
20 March 2024